AbbVie invests US$223 million to expand biologics manufacturing capacity in Singapore.
This new investment will increase an additional 24,000 litres of biologics drug-substance capacity to manufacturing network. This expansion is poised to bolster existing product lines and provide essential support for upcoming immunology and oncology compounds within the pipeline.
The expansion will enhance global manufacturing capabilities, facilitating the growth of biologics pipeline. This investment underscores dedication to meeting patient commitments both now and in the future.
After completion, the new expansion will increase the biologics manufacturing capacity within the global network and create over 100 new job opportunities in Singapore.
Once fully operational, the expanded manufacturing facility will employ over 500 individuals across various roles including manufacturing, quality assurance, supply chain, engineering, and administration.
Construction for the expansion is slated to commence later this year, with operations anticipated to begin in 2026.
Budget US$223 million